More Articles

International supply side policies for biosimilars Reports | Posted 30/11/2018

A report published by the Canadian Agency for Drugs and Technologies in Health (CADTH) investigated how international supply side policies influenced the use of biosimilars [1].

EC approval for pegfilgrastim biosimilars Pelmeg and Ziextenzo Biosimilars/News | Posted 30/11/2018

In November 2018, pegfilgrastim biosimilars, Pelmeg and Ziextenzo, received European Commission (EC) approval.

Switching from reference products to biosimilars: the European perspective Biosimilars/Research | Posted 30/11/2018

The number of biosimilars receiving marketing authorization has grown steadily over the past several years [1, 2] and is expected to continue growing in the future. Particularly when biologicals ar...

Effectiveness of chronic hepatitis C treatment using direct-acting antivirals: real-life data Generics/Research | Posted 30/11/2018

Hepatitis is an inflammation of the liver and can be caused by medications, toxins, severe alcohol use and other medical conditions. Hepatitis can also be caused by viruses, most commonly hepatitis...

FDA approves more generics in 2018 than any other year Generics/General | Posted 30/11/2018

The US Food and Drug Administration (FDA) approved 971 generics in 2018, more than in any previous year, according to the Activities Report of the Generic Drug Program (FY 2018).

Comparative results for CT-P10 in low-tumour burden FL Biosimilars/Research | Posted 30/11/2018

According to research in patients with low-tumour burden follicular lymphoma (FL), the efficacy and pharmacokinetics of rituximab biosimilar CT‑P10 are equivalent or non-inferior to the originator...

Patient, health and trade groups say USMCA will keep drug prices high Policies & Legislation | Posted 30/11/2018

Patient, healthcare and trade groups have warned that the North American Free Trade Agreement (NAFTA), now known as the US-Mexico-Canada Free Trade Agreement (USMCA) will keep American drug prices...

Alvotech makes deal with Fuji Pharma for biosimilars in Japan Pharma News | Posted 30/11/2018

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.